Download PDF
Pharmacopsychiatry 2004; 37: 166-170
DOI: 10.1055/s-2004-832674
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Sigma Receptors and Sigma Ligands: Background to a Pharmacological Enigma

B. E. Leonard1
  • 1Pharmacology Department, National University of Ireland, Galway and Department of Psychiatry and Neuropsychology, University of Maastricht, The Netherlands
Further Information

Publication History

Publication Date:
17 November 2004 (online)

Also available at
    Permissions and Reprints

Although it is now well established that the sigma receptors are distinct from neurotransmitter, neuropeptide and steroid receptors, their precise physiological role, and possible involvement in the pathology of neurological and psychiatric disorders, remains an enigma. The purpose of this short review is to provide a basis upon which to explain the pharmacological properties of such a diverse group of drugs as the antidepressants, antipsychotics and neuroprotective agents. However, a greater understanding of the importance of the sigma receptors will depend on the development of more potent and selective sigma agonists and antagonists if the therapeutic potential of the sigma receptors is to be fully realised.

Key words

sigma-1 - sigma-2 receptors - endogenous ligands - antidepressants - antipsychotics - SSRI’s - dystonia

References

  • 1 Bergeron R, DeBonnel G, de Montigny C. Modification of the NMDA response by antidepressant sigma receptor ligands.  Eur J Pharmacol. 1993;  240 319-323
    CrossrefPubMedGoogle Scholar
  • 2 Bergeron R, de Montigny C, DeBonnel G. Bipohasic effects of sigma ligands on the neuronal response to N-methyl-D-aspartate.  Naunyn-Schmiedeberg’s Arch Pharmacol. 1996;  351 252-260
    PubMedGoogle Scholar
  • 3 Bowen W D, Tolentino P, Varghese P. Investigation of the mechanism by which sigma ligands inhibit stimulation of phosphoinositide metabolism by muscarinic cholinergic agonists.  Prog Clin Biol Res. 1989;  328 21-24
    PubMedGoogle Scholar
  • 4 Clay G A, Brougham L R. Haloperidol binding to an opiate receptor site.  Biochem Pharmacol. 1975;  24 1363-1367
    CrossrefPubMedGoogle Scholar
  • 5 Conner M A, Chavkin C. Ionic zinc may function as an endogenous ligand for haloperidol sensitive sigma-2 receptor in rat brain.  Mool Pharmacol. 1992;  42 471-479
    PubMedGoogle Scholar
  • 6 Contreras P C, Di Maggio D A, O’Donohue T L. An endogenous ligand for the sigma opioid binding site.  Synapse. 1987;  1 57-61
    CrossrefPubMedGoogle Scholar
  • 7 Deutsch S L, Weizman A, Goldman M E, Morihisa J M. The sigma-receptor:a novel site implicated in psychosis and antipsychotic drug efficacy.  Clin Neuropharmacol. 1988;  11 105-119
    PubMedGoogle Scholar
  • 8 Faherty C J, Harkin A J, Leonard B E. The functional modulation of sigma receptors following chronic SSRI treatment. Eur J Pharmacol 1997
    Google Scholar
  • 9 Gray N M, Contreras P C, Allen S E, Taylor D P. H1 antihistamines interact with central sigma receptors.  Life Sci. 1990;  47 175-180
    CrossrefPubMedGoogle Scholar
  • 10 Harris L S, Pierson A K. Some narcotic antagonistsin the benzomerphan series.  J Pharmacol Exp Ther . 1964;  143 141-148
    PubMedGoogle Scholar
  • 11 Itzhak Y, Kassim C O. Clorgyline displays high affinity for sigma sites in C57-BL/6 mouse brain.  Eur J Pharmacol. 1990;  176 107-108
    CrossrefPubMedGoogle Scholar
  • 12 Itzhak Y, Mash D, Zhang S H, Stin I. Characterization of MPTP binding sites in C57 BL/6 mouse brain;mutual effects of monoamine oxidase inhibitors and sigma ligands on MPTP and sigma binding sites.  Mol Pharmacol. 1991;  39 385-393
    PubMedGoogle Scholar
  • 13 Ivory J D. The effects of putative antipsychotic drugs and antidepressants on sigma receptors in the rat brain M.Sc thesis. National University of Ireland Galway; 1994
    Google Scholar
  • 14 Junien J -L, Gue M, Bbueno L. Neuropeptide-Y and sigma ligand Jo 1784 act through a Gi protein to block the psychological stress and CRF induced colonic motor activation in rats.  Neuropharmacol. 1991;  30 119-124
    CrossrefPubMedGoogle Scholar
  • 15 Klein M, Carroll P D, Musacchio J M. SKF-525A and cytochrome P450 ligands inhibit with high affinity the binding of 3H-dextromethorphan and ligands to guinea pig brain.  Life Sci. 1991;  48 543-550
    CrossrefPubMedGoogle Scholar
  • 16 Konig F, von Hippel C, Petersdorff T, Neuhoffer-Weiss M, Wolfersdorf M, Kaschka W P. First experiences in combination therapy using olanzapine with SSRI’s (citalopram, paroxetine) in delusional depression.  Neuropsychobiol. 2001;  43 170-174
    PubMedGoogle Scholar
  • 17 Lammers C H, Deuschle M, Weigmann H, Hartter S, Hiemke C, Hesse C, Heuser I. Coadministration of clozapine and fluvoxamine in psychotic patients-clinical experience.  Pharmacopsychiat. 1999;  32 76-77
    PubMedGoogle Scholar
  • 18 Largent B L, Wikstrom H, Gunlach A L, Snyder S H. Structural determinants of sigma receptor affinity.  Mol Pharmacol. 1987;  32 772-784
    PubMedGoogle Scholar
  • 19 Lasagna L, Beecher H K. The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man.  J Pharmacol Exp Ther. 1954;  112 356-363
    PubMedGoogle Scholar
  • 20 Leonard B E, Faherty C J. SSRI’s and movement disorders: is serotonin the culprit?.  Hum Psychopharmacol. 1996;  11(suppl.2) S 75-82
    PubMedGoogle Scholar
  • 21 Leonard B E, Nicholson C D. Ssigma ligands ars potential psychotropic drugs.  J Psychopharmacol. 1994;  8 64-65
    PubMedGoogle Scholar
  • 22 McCann D J, Weissman A D, Su J- P. Sigma-1 and sigma-2 sites in rat brain: comparison of regional ontogenetic and subcellular patterns.  Synapse. 1994;  17 182-189
    CrossrefPubMedGoogle Scholar
  • 23 Magnan J, Patterson S J, Tavani A, Zosterlitz H W. The binding spectrum of narcotic analgesics with different agonists and antagonist properties.  Nauyn-Schmiedeberg’s Arch Pharmacol. 1982;  319 197-319
    PubMedGoogle Scholar
  • 24 Martin W R, Eades C G, Thompson W O, Huppler R E, Glibert P E. The effect of morphine and nalorphine-like drugs in the non-dependent and morphine-dependent chronic spinal dog.  J Pharmacol Exp Ther. 1976;  197 517-532
    PubMedGoogle Scholar
  • 25 Matsumoto R R, Walker J M. Iontophoretic effects of putative sigma ligands on rubral neurons in the rat Brain Res.  Bull. 1992;  29 419-425
    PubMedGoogle Scholar
  • 26 Monnet F P, DeBonnel G, de Montigny C. Neuropeptide-Y selectively potentiates NMDA induced neuronal activation.  Eur J Phharmacol. 1990;  182 207-208
    CrossrefPubMedGoogle Scholar
  • 27 Monnet F P, Mahe V, Robel P, Beulien E D. Neurosteroids, via sigma receptors, modulate the 3H-noradrenaline release evoked by N-methyl-D-aspartate in the rathippocampus.  Proc Natl Acad Sci USA. 1995;  92 3774-3778
    PubMedGoogle Scholar
  • 28 Narita N, Hashimoto K, Tomitaki S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sugma receptor in rat brain.  Eur J Pharmacol. 1996;  307 117-119
    PubMedGoogle Scholar
  • 29 Paul I A, Nowak G, Layer R T, Popik P, Skolnick P. Adaptation of ther NMDA receptor complex following chronic antidepressant treatments.  J Pharmacol Exp Ther. 1994;  269 95-102
    PubMedGoogle Scholar
  • 30 Quirion R, Chicheportiche R, Contreras P C, Johnson K M, Lodge D. Classification and nomenclature of phencyclidine and sigma receptor sites.  TINS. 1987;  10 444-446
    PubMedGoogle Scholar
  • 31 Quirion R, Bowen W D, Itzhak Y, Junien J- L, Musacchio R B. A proposal for the classification of sigma binding sites.  TIPS. 1992;  13 85-87
    CrossrefPubMedGoogle Scholar
  • 32 Reddy D S, Kaur G, Kulkarni S K. Sigma-1 receptor mediated anti-depressant -like effects of neurosteroids in the Porsolt forced swim test.  Neuroreport. 1989;  9 3069-3073
    PubMedGoogle Scholar
  • 33 Redrobe J P, Carvajal C, Kask A, Dumont Y, Quirion R. Neuropeptide-Y and its receptor subtypes in the central nervous system: emphasis on their role in animal models of psychiatric disorders.  In: Neuropeptide -Y and related peptides. Ed. michel MC Springer Verlag Berlin; 2004: pp 101-136
    Google Scholar
  • 34 Rothschild A J, Samson J A, Bessette M P, Carter-Campbell J T. Efficacy of the combination of fluoxetine and perphenazine in the treartment of psychotic depression.  J Clin Psychiat. 1993;  54 338-342
    PubMedGoogle Scholar
  • 35 Schmidt A, Lebel L, Koe B K, Seeger T, Heym J. Sertraline potently displaces (+)-3H-PPP binding to sites in the rat brain.  Eur J Pharmacol. 1989;  165 335-336
    CrossrefPubMedGoogle Scholar
  • 36 Spiker D G, Weiss J C, Dealy R S. The [pharmacological treatment of delusional depression AMER.  J Psychiat. 1985;  142 430-436
    PubMedGoogle Scholar
  • 37 Stahl S M, Shayegan D. New discoveries in the development of antipsychotics with novel mechanisms of action: beyond the atypical antipsychotics with serotonin dopamine antagonism.  In: Atypical Antipsychotics. Eds. Ellenbroek BA, Cools AR Academic Press NY 2000: pp 215-232
    Google Scholar
  • 38 Su T- P, Weissman A D, Yeh S- Y. Endogenous ligands for sigma opioid receptors in the brain: evidence from binding assays.  Life Sci. 1986;  38 2199-2210
    CrossrefPubMedGoogle Scholar
  • 39 Su T- P, London E D, Jaffe J H. Steroid binding at sigma receptors suggests a link between endocrine, neurotransmitter and immune systems.  Science. 1988;  240 219-221
    PubMedGoogle Scholar
  • 40 Takebayashi M, Hayashi T, Su T- P. Nerve growth factor-induced neurite prouting in PC12 cells involves sigma-receptors: implications for antidepressants.  J Pharmacol Exp Ther. 2002;  303 1227-1237
    CrossrefPubMedGoogle Scholar
  • 41 Tam S W, Cook L. Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-SKF-10 047 and 3H-haloperidol binding in guines pig brain membranes.  Proc Natl Acad Sci USA. 1984;  81 5618-5621
    PubMedGoogle Scholar
  • 42 Taylor D P, Shukla U A, Wolfe S A, Owen P Q, Pyke R, DeSouza E B. Phase 1 trials of BMY 14 802, a potential antipsychotic with affinity for sigma binding sites.  Schizophrenia Res. 1991;  4 327.u
    PubMedGoogle Scholar
  • 43 Walker J M, Matsumato R R, Bowen W D, Gans D L, Jones K D, Walker F O. Evidence for the role of haloperidol -sensitive sigma opiate receptors in the motor effects of antipsychotic drugs.  Neurology. 1988;  38 961-965
    PubMedGoogle Scholar
  • 44 Walker J M, Bowen W D, Walker F O, Matsumoto R R, de Costa B, Rice K C. Sigma receptors: biology and function.  Pharmacol Revs. 1990;  42 356-401
    PubMedGoogle Scholar
  • 45 Yamamoto H, Yamamoto Y, Sagi N, Klenerova V, Goji K. Sigma ligands indirectly modulate the NMDA receptor ion channel complex on intact neuronal cells via sigma-1 sites.  J Neurosci. 1995;  15 731-736
    PubMedGoogle Scholar
  • 46 Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E. Double-blind controlled trial of sertraline verses paroxetine in the treatment of delusional depression.  Am J Psychiat. 1996;  153 1631-1633
    PubMedGoogle Scholar
  • 47 Zanardi R, Franchini L, Gasperini M, Lucca A, Smeraldi E, Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study.  J Clin Psychopharmacol. 1998;  18 441-446
    CrossrefPubMedGoogle Scholar
  • 48 Zhang A Z, Mitchell K N, Cook L, Tam S W. Human endogenous brain ligands for the sigma opioid and phencyclidine receptors.  In: Sigma and phencyclidine - like compounds as molecular probes in biology. Eds. Domino EF, Kameuka JM. NPP Books, Ann Arbor, MI 1988: pp. 335-343
    Google Scholar
  • 49 Zukin R S, Zukin S R. Specific [3H] phencyclidine binding in rat central nervous system.  Proc Natl Acad Sci USA. 1979;  76 5372-5376
    PubMedGoogle Scholar
  • 50 Zukin S R, Zukin R S. Demonstration of [3H] cyclazocine binding to multiple opiate receptor sites.  Mol Pharmacol. 1981;  20 246-254
    PubMedGoogle Scholar
  • 51 Zukin S R, Tempel A, Gardner E L, Zukein R S. Interaction of 3H-(-) SKF 10 047 with brain sigma receptors: characterization and autoradiographic visualization.  J Neurosci. 1986;  46 1032-1041
    PubMedGoogle Scholar

Prof. Dr. Brian E. Leonhard

National University of Ireland

Pharmacology Department

Galway

Irland

Email: bel@nuigalway.ie